Initial testing (Stage 1) of TAK‐701, a humanized hepatocyte growth factor binding antibody, by the pediatric preclinical testing program

@article{Houghton2014InitialT,
  title={Initial testing (Stage 1) of TAK‐701, a humanized hepatocyte growth factor binding antibody, by the pediatric preclinical testing program},
  author={P. Houghton and R. Kurmasheva and E. Kolb and J. Wu and R. Gorlick and J. Maris and M. Smith},
  journal={Pediatric Blood & Cancer},
  year={2014},
  volume={61}
}
  • P. Houghton, R. Kurmasheva, +4 authors M. Smith
  • Published 2014
  • Medicine
  • Pediatric Blood & Cancer
    • TAK‐701 is a humanized antibody that binds hepatocyte growth factor (HGF), thus suppressing c‐Met transduced signaling and c‐Met dependent proliferation and migration of tumor cells. Six childhood solid tumor xenografts were selected for evaluating TAK‐701 based on immunochemical detection of HGF/c‐Met autocrine signaling [i.e., pMet(Tyr1349) and HGF positive]. TAK‐701 was tested using a dose of 30 mg/kg administered by the intraperitoneal (IP) route twice weekly for 4 weeks. TAK‐701 did not… CONTINUE READING
    View on Wiley
    europepmc.org
    5 Citations

    Topics from this paper

    Explore Further: Topics Discussed in This Paper

      5 Citations
      Citation Type

      Citation Type

      Targeting the oncogenic Met receptor by antibodies and gene therapy
      • 33
      • PDF
      The HGF/MET Signaling and Therapeutics in Cancer
      • 4
      Whole exome profiling and mutational analysis of Ocular Surface Squamous Neoplasia.
      Regulation of Signal Transduction in Human Cell Research
      • 2
      Targeting HGF with Antibodies as an Anti‐Cancer Therapeutic Strategy

      References

      SHOWING 1-10 OF 19 REFERENCES
      Abstract #1244: Monotherapeutic and combination antitumor activities of TAK-701, a humanized anti-hepatocyte growth factor neutralizing antibody, against multiple types of cancer
      • 8
      Novel xenograft model expressing human hepatocyte growth factor shows ligand-dependent growth of c-Met–expressing tumors
      • 24
      • PDF
      PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells
      • 41
      • PDF
      TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived HGF in Non–Small Cell Lung Cancer with an EGFR Mutation
      • 70
      • PDF
      Initial testing of VNP40101M (Cloretazine®) by the pediatric preclinical testing program
      • 7
      Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor
      • 70
      • PDF
      Hepatocyte Growth Factor/c-Met Signaling Promotes the Progression of Experimental Human Neuroblastomas
      • 70
      • PDF
      The MET receptor tyrosine kinase contributes to invasive tumour growth in rhabdomyosarcomas
      • 41
      The pediatric preclinical testing program: Description of models and early testing results
      • 385
      Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy.
      • 180
      • PDF